SHARE - Symbicort and Health Economics in a Real Life Evaluation
Study identifier:D5890L00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Symbicort and Health Economics in a Real Life Evaluation – SHARE – A Randomised, Open-Label, Parallel-Group, Multicentre Study to Assess the Asthma-Related Health-Care Costs, in Ordinary Clinical Practice During 12 Months
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
Budesonide, Formoterol, Terbutaline
Sex
All
Actual Enrollment
1970
Study type
Interventional
Age
12 Years +
Date
Study Start Date: 01 Apr 2004
Primary Completion Date: -
Study Completion Date: 01 May 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Symbicort Medical Science Director
AstraZeneca
